Differentiating Pythium Keratitis From Fungal and Acanthamoeba Keratitis: A Practical Guide

Etiology

The etiopathogenesis of Pythium, fungal, and Acanthamoeba keratitis illustrates how pathogens from different biological kingdoms can produce overlapping corneal infections that are often clinically indistinguishable. The differentiation depends not only on morphology and culture characteristics but also on biochemical composition, environmental reservoirs, and mechanisms of corneal invasion. Understanding these distinctions is critical to implementing appropriate therapy, as each pathogen responds differently to medical management.[8] Table 4 summarizes the differences between the 3 organisms.

Pythium Keratitis

Pythium insidiosum is an aquatic oomycete, a fungus-like eukaryote belonging to the kingdom Straminipila (Chromista), phylum Oomycota, and order Pythiales. P insidiosum is not a true fungus, although its hyphal morphology mimics fungal filaments on microscopy, often leading to initial diagnostic confusion.[9]

Biological and structural characteristics:

Unlike fungi, Pythium spp possess cellulose and β-glucans in their cell walls instead of chitin, and the plasma membrane lacks ergosterol. This structure explains intrinsic resistance to most antifungal agents. The organism reproduces both sexually (via oospores) and asexually (via biflagellate zoospores). These motile zoospores are the infective form responsible for corneal inoculation.[10]

Environmental and epidemiological context:

P insidiosum thrives in stagnant or slow-moving freshwater, paddy fields, and muddy soil, particularly in humid, tropical, and subtropical climates. The geographic distribution mirrors agricultural and monsoon patterns, with seasonal surges reported in India, Thailand, northern Australia, and the southeastern US. Studies from India (Gurnani et al, 2022) and Thailand have shown that P insidiosum accounts for 10% to 15% of culture-negative fungal keratitis cases in endemic regions, particularly during the monsoon months (June through September).[11]

Predisposing factors:

The infection commonly follows corneal trauma, contamination with soil or vegetative material, or direct exposure to muddy water during agricultural activities. Additional risk factors include the following:

• Prolonged use of topical antifungals without improvement (suggesting misdiagnosis)
• Contact lens wear with contaminated solutions or poor hygiene
• Ocular surface disease (dry eye, exposure keratopathy)
• Poor socioeconomic and sanitary conditions in rural populations [12]

Mechanism of infection:

The infection begins when zoospores adhere to damaged corneal epithelium, guided by chemotaxis toward exposed collagen. They encyst, germinate, and penetrate the stroma, secreting proteolytic, lipolytic, and cellulolytic enzymes that facilitate tissue invasion. Resulting stromal destruction produces the hallmark reticular or tentacular gray-white infiltrate with minimal necrosis but rapid progression.

Unique features:

Pythium spp filamentous hyphae are broad, ribbon-like, and aseptate, mimicking Mucorales spp but with distinct cellulosic staining patterns (PAS-positive, variably Grocott-Gomori methenamine silver [GMS]-positive). In culture, Pythium spp form a flat, colorless colony on blood agar and do not sporulate on routine fungal media, such as Sabouraud dextrose agar. Leaf-incubation methods and PCR assays targeting the internal transcribed spacer region confirm the diagnosis.[13]

Fungal Keratitis

Fungal keratitis (mycotic keratitis) is caused by true fungi, belonging to the kingdom Fungi, and represents the most common cause of microbial keratitis in tropical countries. Common etiologic agents include filamentous fungi (Fusarium spp, Aspergillus spp, Curvularia spp, and Alternaria spp) and yeasts (Candida albicans).[14]

Environmental and biological characteristics:

Fungal spores are ubiquitous, occurring as saprophytes in soil, on decomposing vegetation, and in the air. Their chitin-rich cell wall and ergosterol-containing plasma membrane are targets of antifungal agents such as natamycin and voriconazole.

Predisposing factors:

Fungal keratitis typically occurs after corneal trauma with vegetative matter, contact lens wear, or preexisting ocular surface disease. Additional risk factors include long-term corticosteroid use, diabetes mellitus, and chronic ocular surface inflammation.[15]

Mechanism of infection:

Following epithelial trauma, fungal spores adhere to the corneal surface and germinate into hyphae that invade through stromal lamellae. The infection progresses slowly, eliciting a granulomatous or mixed inflammatory response. Clinically, it manifests as a feathery-edged infiltrate with satellite lesions, necrotic slough, and stromal thinning. In severe cases, an endothelial plaque and hypopyon form, leading to late-stage perforation.

Geographic and climatic association:

Fungal keratitis is prevalent in tropical and subtropical regions, with Fusarium spp dominating in warm, humid areas and Aspergillus spp in temperate climates. Please see StatPearls' companion resource, "Keratoconjunctivitis," for further information.

Acanthamoeba Keratitis

Acanthamoeba keratitis is a protozoal infection of the cornea caused by Acanthamoeba castellanii, A polyphaga, or A culbertsoni. The organism belongs to the kingdom Protista and exists in 2 forms: the active trophozoite and the resistant double-walled cyst. Both forms can be pathogenic.

Environmental and biological characteristics:

Acanthamoebae organisms are free-living amoeba found in soil, freshwater, swimming pools, and contact lens solutions. The cyst form can survive extreme environmental conditions and disinfectants, thereby complicating eradication.[16]

Predisposing factors:

The most common predisposing factor is contact lens wear, particularly when lenses are rinsed with tap water or worn during swimming. Other risk factors include corneal trauma, exposure to contaminated water, poor hygiene, and use of homemade saline solutions.

Mechanism of infection:

Infection begins when trophozoites attach to the corneal epithelium via mannose-binding proteins, leading to epithelial disruption and stromal penetration. The organism follows perineural pathways, causing severe pain disproportionate to the lesion. Histologically, cysts and trophozoites can be found clustered along corneal nerves.[17]

Pathologic hallmark:

The disease is characterized by radial keratoneuritis in early stages and a ring-shaped stromal infiltrate in advanced stages. Chronic infection and cyst resistance to therapy make management prolonged and challenging.

Table 4. Comparative Etiologic Summary

Integrative Perspective

While all 3 pathogens infect via an epithelial breach, their survival strategies and pathogenic mechanisms differ. P insidiosum exploits aquatic conditions and enzymatic destruction for rapid tissue invasion; fungi rely on spore germination and hyphal growth with necrotizing inflammation; Acanthamoeba spp capitalize on neural pathways and cystic resistance for chronic persistence. Misidentification is common because Pythium spp mimic fungal hyphae on microscopy, and Acanthamoeba spp can clinically resemble viral or sterile keratitis. The key differentiator lies in the biological composition of their cell walls and membranes, which dictates drug susceptibility: P insidiosum requires antibiotic-based antioomycete therapy, fungi respond to antifungal agents, and Acanthamoeba requires cysticidal biguanides. In summary, P insidiosum keratitis represents an emerging, environmentally acquired, waterborne corneal infection distinct in origin, structure, and treatment response from fungal and amoebic keratitis. Differentiation based on etiology, environmental exposure, and therapeutic behavior is the cornerstone of preventing mismanagement and improving visual outcomes.[18]

Epidemiology

The global epidemiology of infectious keratitis reveals distinct geographic, demographic, and environmental patterns for Pythium, fungal, and Acanthamoeba infections. While all 3 can cause corneal ulcers that clinically mimic one another, their distribution, seasonal trends, host profiles, and risk exposures vary considerably. Recognizing these epidemiologic nuances is crucial for early clinical suspicion and appropriate microbiological work-up.[19] Table 5 summarizes the epidemiology of each organism.

Pythium insidiosum keratitis is increasingly reported in tropical and subtropical regions, with the highest incidence in Southeast Asia and South Asia. First described in Thailand and India, it has emerged as an important pathogen in humid agricultural belts. In India, the disease is endemic in Tamil Nadu, Kerala, Madhya Pradesh, Rajasthan, and Odisha, particularly during the monsoon and postmonsoon seasons when exposure to muddy water is frequent. Epidemiologic studies by Gurnani et al and Bagga et al report that 10% to 15% of culture-negative fungal keratitis cases in western and southern India are later identified as P insidiosum using molecular testing or specialized culture methods. Globally, sporadic cases have been documented in Australia (Queensland and Northern Territory), China, and the US, typically associated with aquatic exposure or contact with animals (eg, horses, dogs). No strong sex predilection has been reported; however, a slight male predominance (60% to 65%) has been observed, likely reflecting occupational exposure among farmers and outdoor laborers. The affected age range is 30 to 50 years, although pediatric and geriatric cases are increasing. Seasonal peaks coincide with rainfall and irrigation cycles, with a surge from July to October in monsoon climates. The incidence is notably low in temperate regions, where P insidiosum is more commonly associated with zoonotic infections than with human ocular disease.[20]

In contrast, fungal keratitis has the highest global burden among microbial keratitis cases, accounting for 40% to 50% of all corneal ulcers in tropical regions. The prevalence varies widely by geography: highest in South and Southeast Asia, moderate in Africa and South America, and relatively low in North America and Europe. An extensive multicenter analysis (Ung et al, 2022) estimated that fungal keratitis affects more than 1 million people worldwide annually, with 100,000 eyes lost to perforation or blindness. Fusarium species predominate in humid agricultural zones (India, Nepal, Thailand, southern China, and sub-Saharan Africa), whereas Aspergillus spp and Curvularia spp are common in drier areas. The disease exhibits a male preponderance (70%-80%), primarily because men more frequently engage in outdoor, agricultural, or manual labor. The incidence peaks in those aged 20 to 55 years, corresponding to the economically active population. In resource-rich areas, contact lens-related fungal keratitis is more prevalent, particularly with Fusarium solani. Seasonal distribution aligns with harvest periods and monsoon months. Rural populations are disproportionately affected, and limited access to microbiologic testing contributes to misdiagnosis and delayed antifungal therapy.[21]

Acanthamoeba keratitis exhibits a bimodal geographic distribution, being more prevalent in developed, contact-lens–using populations and in rural regions with poor water hygiene. The global incidence is estimated at 1 to 2 cases per million contact lens wearers annually, but this estimate may be underreported. In the US and Europe, 85% to 90% of cases are associated with soft contact lens wear, particularly improper cleaning, exposure to tap water, or swimming with lenses. In contrast, in resource-limited regions like India, Nepal, and Africa, cases linked to trauma, contaminated water exposure, or topical corticosteroid misuse are more prevalent. The disease affects both sexes equally, with a median age of 20 to 40 years. Urban incidence correlates with the popularity of cosmetic and extended-wear lenses. Unlike infections caused by Pythium spp or other fungi, Acanthamoeba infections are not seasonal, although outbreaks often coincide with increased recreational water use in the summer months. Please see StatPearls' companion resource, "Acanthamoeba Keratitis," for further information.

The environmental niche of each pathogen explains its demographic pattern. Pythium spp infections are prevalent in agricultural zones, where standing water and wet soil promote zoospore survival, whereas fungal keratitis is associated with harvest-related corneal trauma from plant material. Conversely, Acanthamoeba keratitis is prevalent in urban, contact lens–using populations, where chlorinated water and inadequate hygiene enable cyst survival. In the US and Europe, Pythium and fungal keratitis are rare, typically acquired through travel or agricultural exposure, whereas Acanthamoeba infections are a recognized public health concern in ophthalmic practice. In India and Southeast Asia, Pythium and fungal keratitis together constitute the major causes of nonbacterial corneal ulcers, with Pythium increasingly recognized as an emerging zoonotic threat.

In summary, Pythium keratitis primarily affects men in rural, agricultural, humid, and tropical areas. Fungal keratitis remains the leading cause of microbial keratitis globally. Acanthamoeba keratitis is increasingly observed among urban contact lens users. These epidemiological distinctions are critical for early differential diagnosis, guiding clinicians toward appropriate microbiologic testing and tailored therapy based on regional exposure patterns. Please see StatPearls' companion resource, "Contact Lens-Related Complication," for further information.

Table 5. Epidemiology of Causative Organisms in Keratitis

Pathophysiology

The pathophysiology of Pythium insidiosum, fungal, and Acanthamoeba keratitis differs significantly, reflecting their distinct phylogenetic origins and modes of host interaction. While all 3 pathogens cause corneal inflammation through epithelial breach, stromal invasion, and immune activation, their patterns of tissue destruction, cellular tropism, and host inflammatory responses are distinct.

Pythium insidiosum Keratitis

Pythium insidiosum is an aquatic oomycete that mimics filamentous fungi morphologically but is phylogenetically closer to algae. The biflagellate motile zoospores are the infective stage. These zoospores exhibit chemotaxis toward injured corneal epithelium, attracted by corneal amino acids, lipids, and carbohydrates. Upon reaching the corneal surface, they encyst and germinate into aseptate, filamentous hyphae that penetrate the stroma. The organism’s cell wall is composed of cellulose and β-glucans instead of chitin, and its plasma membrane lacks ergosterol. This structural composition accounts for resistance to conventional antifungal agents and a predisposition to rapid stromal invasion. Once established in the corneal stroma, P insidiosum secretes an array of hydrolytic enzymes, including proteases, lipases, esterases, and cellulases, which digest collagen and keratocytes, resulting in stromal necrosis and lamellar disorganization. The infiltrate adopts a reticular or tenacular pattern, corresponding to hyphal extensions along stromal lamellae.[13]

Host recognition occurs through pattern recognition receptors on corneal epithelial and immune cells, triggering innate immune activation via Toll-like receptor–mediated pathways. The ensuing neutrophilic infiltration and cytokine release (IL-1β, IL-6, tumor necrosis factor–α [TNF-α]) exacerbate tissue damage. The organism’s biofilm-like growth and its ability to evade oxidative killing allow it to persist despite inflammation. In advanced stages, P insidiosum invades the Descemet membrane and endothelium, forming endothelial plaques and hypopyon, with potential extension into the sclera. The pathophysiologic hallmark of Pythium keratitis is rapid stromal destruction with minimal suppuration, producing a dry, gray-white reticular ulcer that progresses centrifugally. The organism’s enzymatic aggression, poor immune clearance, and antifungal resistance culminate in rapid perforation unless the organism is surgically excised.[22]

Fungal Keratitis

Fungal keratitis arises from infection by filamentous or yeast-like fungi, typically Fusarium, Aspergillus, or Candida spp. The infection begins when fungal spores adhere to a disrupted epithelial surface and germinate into septate branching hyphae. These hyphae penetrate the Bowman layer and corneal stroma, releasing keratinases, collagenases, and phospholipases that digest the extracellular matrix. The fungi elicit a granulomatous inflammatory response with macrophages, multinucleated giant cells, and lymphocytes surrounding fungal filaments. This immune reaction produces necrotic sloughing and stromal edema, resulting in the classic feathery-edged infiltrate with satellite lesions.[23]

As hyphae advance, they extend along corneal lamellae, promote localized ischemia, and contribute to endothelial damage. The host immune response contributes significantly to tissue injury. Toll-like receptor 2 and dectin-1 signaling activate nuclear factor kappa-light-chain enhancer of activated B-cell pathways, upregulating IL-8 and TNF-α, which recruit neutrophils. These cells, while microbicidal, also release matrix metalloproteinases that intensify stromal melt. The chronic phase is characterized by fibrosis and neovascularization, resulting in scarring. In Candida keratitis, the yeast invades deeper corneal layers, leading to suppuration and abscess formation rather than dry necrosis.[24]

Acanthamoeba Keratitis

Acanthamoeba species are freeliving protozoa with 2 life stages—trophozoite (active) and cyst (dormant). The trophozoite stage initiates infection by adhering to damaged corneal epithelium, a process mediated by mannose-binding proteins on the amoebic surface that recognize mannose residues on epithelial glycoproteins. After attachment, Acanthamoeba spp secretes proteases (serine and cysteine proteases), phospholipases, and neuraminidases, leading to epithelial lysis and apoptosis. The trophozoites penetrate the stroma, often traveling along corneal nerves (perineural spread). This neural invasion results in radial keratoneuritis, which explains the intense, disproportionate pain that is a hallmark of this disease.[25]

Within the stroma, Acanthamoeba organisms alternate between trophozoite and cyst forms in response to nutrient and oxygen availability. The cyst form, with a double-walled structure composed of cellulose and glycoproteins, confers resistance to host defenses and medications. Chronic infection leads to ring-shaped stromal infiltrate, dense scarring, and recurrent inflammation due to cyst reactivation. The host immune response is predominantly cell-mediated, involving T helper 1 cytokines (interleukin-12 and interferon γ) and macrophage activation. However, ineffective clearance allows persistent infection and chronic inflammation.[26]

Integrated Pathophysiologic Summary

All 3 pathogens exploit an epithelial breach as the entry point into the cornea, but their downstream mechanisms differ profoundly. Pythium spp uses motile zoospores to locate and colonize damaged tissue, spreading rapidly through enzymatic degradation and limited host containment. Fungal pathogens rely on spore germination and chronic granulomatous inflammation, resulting in necrotic slough and delayed healing. In contrast, Acanthamoeba spp exhibit neurotropic invasion and cystic persistence, leading to chronic pain and recurrent disease. In Pythium infections, the combination of rapid enzyme-mediated tissue lysis, antifungal resistance, and immune-mediated collateral damage results in a highly aggressive ulcer that often perforates early. In fungal infections, chronic inflammation and necrosis dominate, whereas Acanthamoeba infection primarily induces neuritis and chronic stromal inflammation.

Although the clinical manifestations (corneal ulcer, infiltrate, and hypopyon) may appear similar, the underlying cellular and immunopathologic mechanisms are distinct. This understanding underscores why Pythium infections require early antibiotic-based therapy or keratoplasty, fungi require antifungal therapy, and Acanthamoeba infections require cysticidal treatment with biguanides, each tailored to the organism’s unique biology and host interactions.[27] Table 6 compares the pathophysiology of the 3 organisms.

Table 6. Pathophysiology of Keratitis

Histopathology

Microscopic examination of corneal tissue is pivotal for distinguishing Pythium insidiosum from fungal and Acanthamoeba keratitis. Each organism exhibits distinct morphologic and staining characteristics that reflect its biological composition and pathologic interaction with the cornea. Understanding these histopathological signatures is essential for accurate diagnosis, particularly in cases that are unresponsive to standard antifungal therapy. Table 7 compares the histopathology of each organism.

Pythium insidiosum Keratitis

Histopathologically, Pythium keratitis displays aseptate or sparsely septate, broad, ribbon-like filaments that infiltrate the stroma in a reticular or net-like pattern. The filaments typically measure 3 to 8 μm in diameter, have irregular contours, and often branch at right or wide angles. Unlike true fungal hyphae, Pythium filaments lack chitin and ergosterol, and they do not show parallel walls or dichotomous branching.[28]

Tissue localization and reaction:

The organism primarily affects the anterior and midstroma, although deeper layers, including the Descemet membrane, may be invaded in advanced disease. The stroma shows intense neutrophilic infiltration, stromal edema, and focal necrosis, with minimal granulomatous reaction. Limbal and scleral extension may be observed in progressive stages.

Staining characteristics:

• Hematoxylin and eosin (H&E): Filaments appear as refractile, eosinophilic, and poorly septate strands within a necrotic stromal matrix.
• Periodic acid–Schiff (PAS): Positive due to β-glucan and cellulose content; highlights Pythium filaments as light pink to magenta.
• Gomori methenamine silver (GMS): Variable staining, some filaments stain faintly or inconsistently due to the absence of chitin, unlike true fungi.
• Gram stain: Often weakly positive; filaments may appear as Gram-variable.
• Calcofluor White: May exhibit faint fluorescence due to minimal cellulose cross-linking.[29]

Distinctive features:

• Absence of chitin and ergosterol (unlike fungi).
• Lack of fruiting bodies or spores in tissue.
• Necrotic stroma with minimal suppuration, correlating with clinical dry appearance.
• Reticular stromal pattern consistent with tentacular infiltration.

Immunohistochemistry and PCR-based identification (amplification of the internal transcribed spacer 1 [ITS1] and cytochrome c oxidase [COX2] genes) confirm the diagnosis, especially when culture fails. The leaf-incubation technique facilitates sporulation and differentiation in zygomycetes.[19]

Fungal Keratitis

Fungal keratitis is characterized by septate or nonseptate hyphae, depending on the species. Fusarium and Aspergillus species demonstrate septate, slender hyphae (2–5 μm in diameter) with acute-angle (45°) branching, while Mucorales (eg, Rhizopus spp) are broad and aseptate, similar to Pythium but distinguished by their thick walls and stronger GMS affinity.

Tissue features:

The corneal stroma shows dense inflammatory infiltrate comprising neutrophils, macrophages, and multinucleated giant cells, forming a granulomatous reaction around fungal filaments. There is stromal necrosis, keratocyte loss, and edema, often associated with suppuration. In severe cases, fungi penetrate the Descemet membrane, resulting in an endothelial plaque and a hypopyon.[30]

Staining characteristics:

• H&E: Hyphae appear as eosinophilic, refractile, and septate filaments with acute branching.
• PAS and GMS: Strong positivity due to chitin-rich cell walls. GMS stains hyphae black against a green background, providing excellent contrast.
• Calcofluor White: Brilliant blue fluorescence of chitinous filaments under ultraviolet light.

Distinctive features:

• Septate branching hyphae with dichotomous (45°) branching.
• Chitin-rich cell wall confers uniform GMS and Calcofluor White positivity.
• Granulomatous inflammation with suppuration and necrosis.
• Possible endothelial and scleral invasion in advanced cases.[31]

Acanthamoeba Keratitis

Histopathology of Acanthamoeba keratitis demonstrates 2 morphologic forms within the corneal tissue: trophozoites (active) and cysts (dormant). Trophozoites are 15 to 45 μm, irregularly shaped with a single nucleus and a prominent central karyosome. They are usually located along stromal lamellae and corneal nerves, consistent with the organism’s neurotropic nature. Cysts are 10 to 25 μm, round or ovoid with a double-walled structure, an outer ectocyst (irregular, wrinkled) and an inner endocyst (spherical and refractile).

Tissue reaction:

In chronic cases, the stroma shows perineural inflammation (radial keratoneuritis), lymphocytic infiltration, and stromal necrosis. Early infection may show minimal cellular reaction, whereas late-stage disease presents with granulomatous inflammation and fibrosis.[32]

Staining characteristics:

• H&E: Trophozoites appear basophilic with a distinct nucleus and nucleolus; cysts show double-walled morphology.
• PAS: Highlights cyst walls due to polysaccharide content.
• GMS: May weakly stain cysts and trophozoites.
• Calcofluor White: Shows brilliant fluorescence outlining cyst walls.
• Giemsa: Stains trophozoites and cysts blue to violet, facilitating identification.

Distinctive features:

• Double-walled cysts are resistant to degeneration.
• Perineural localization causing neuritis.
• Coexistence of trophozoites and cysts, especially in chronic or recurrent disease.
• The absence of hyphae distinguishes Acanthamoeba keratitis from Pythium and other fungal infections.[9]

Table 7. Comparative Histopathologic Features

Abbreviations: GMS, Gomori methenamine silver; PAS, periodic acid-Schiff staining.

Summary Interpretation

Histopathologically, Pythium keratitis is typified by aseptate, ribbon-like cellulose filaments within a necrotic, inflamed stroma and variable GMS staining, setting it apart from fungal keratitis, which shows septate, chitin-rich hyphae with strong silver staining and granulomatous reaction. Acanthamoeba keratitis is characterized by the presence of trophozoites and double-walled cysts, particularly around corneal nerves, which correlate with its neuritogenic pain. In conclusion, histopathology remains the gold standard for differentiating filamentous and protozoal keratitides, especially in antifungal-refractory ulcers. The combined evaluation of morphology, staining patterns, and host inflammatory response provides the diagnostic clarity necessary for targeted management: antibiotic therapy for Pythium, antifungal therapy for fungi, and cysticidal therapy for Acanthamoeba infections.[33]

Toxicokinetics

Although toxicokinetics traditionally pertains to the absorption, distribution, metabolism, and excretion of toxic substances, in the context of infectious keratitis, it can be interpreted as the pharmacokinetic and tissue-toxicity implications of therapeutic agents used against these pathogens and their interactions with corneal tissue. Understanding these pharmacokinetic and toxicologic relationships is crucial for optimizing treatment efficacy while minimizing iatrogenic damage in Pythium, fungal, and Acanthamoeba keratitis.[34] Table 8 compares the toxicokinetic features of keratitis treatments.

Pythium insidiosum Keratitis

The pharmacologic management of Pythium keratitis presents unique toxicokinetic challenges because the organism’s cell wall lacks chitin and ergosterol—the primary antifungal targets. This structural difference makes Pythium intrinsically resistant to most antifungal drugs (eg, natamycin, voriconazole, amphotericin B), leading to prolonged drug exposure, cumulative epithelial toxicity, and delayed healing.

Antimicrobial agents and kinetics:

The drugs most effective against Pythium are antioomycete antibiotics rather than antifungals, including the following:

• Linezolid (0.2%–0.5% suspension)
• Azithromycin (1% suspension)
• Minocycline (1% suspension)
• Cefazolin (5% suspension) [20]

These antibiotics exhibit concentration-dependent killing, and their therapeutic efficacy depends on maintaining high stromal bioavailability through frequent topical application. However, chronic dosing induces epithelial toxicity, superficial punctate keratopathy, and stromal haze, particularly with macrolides and oxazolidinones.

Corneal pharmacokinetics:

Topical linezolid penetrates the corneal stroma effectively but accumulates in the epithelium, resulting in dose-dependent mitochondrial dysfunction and oxidative stress. Because of its lipophilicity, azithromycin achieves sustained stromal concentrations, but long-term use may cause ocular surface dryness and punctate epithelial erosions.

Postkeratoplasty considerations:

Following therapeutic penetrating keratoplasty (TPK), systemic linezolid achieves moderate aqueous levels but may cause systemic myelosuppression and optic neuropathy with prolonged use (>2 weeks). Hence, systemic therapy is generally limited to short-term courses (7–10 days) and combined with topical maintenance therapy.[35]

Summary:

• Primary toxic-kinetic consideration: Epithelial mitochondrial toxicity from antibiotic accumulation.
• Unique feature: Drug–organism mismatch requiring prolonged antibiotic therapy and surgical excision for definitive cure.[36]

Fungal Keratitis

The toxicokinetic profiles of antifungal agents, particularly natamycin, amphotericin B, and voriconazole, play a significant role in determining therapeutic outcomes and corneal tolerance.

Natamycin (5% suspension):

• Kinetics: Poor stromal penetration; primarily acts on the anterior cornea.
• Toxicity: Prolonged use causes epithelial edema, punctate keratitis, and stromal haze.
• Mechanism: Binds ergosterol in fungal cell membranes, creating pores. Systemic absorption is minimal; however, cumulative irritation of the epithelium may occur with prolonged use.[37]

Voriconazole (1% solution or 200 mg oral):

• Kinetics: Excellent corneal and aqueous penetration; systemic bioavailability is approximately 90%.
• Toxicity: Photosensitivity, hepatotoxicity, and neurotoxicity with systemic administration; topical use may cause burning, redness, and delayed epithelialization.
• Corneal metabolism: The active drug persists in stromal tissue for approximately 6 hours; optimal dosing is every 2 to 3 hours.

Amphotericin B (0.15%–0.5% solution):

• Kinetics: Strong fungicidal action but poor tissue diffusion.
• Toxicity: Epithelial toxicity may cause dense epithelial defects, keratocyte apoptosis, and Descemet folds.
• Mechanism: Induces lipid peroxidation in both fungal and host cell membranes.[38]

Systemic implications:

Oral or intravenous antifungals such as itraconazole and fluconazole, although less toxic to the eye, undergo hepatic metabolism, necessitating monitoring of liver function during prolonged therapy.

Summary:

• Primary toxic kinetic mechanism: Ergosterol-targeted collateral membrane damage to the host corneal epithelium.
• Toxic pattern: Dose- and duration-dependent epithelial and stromal injury, potentiated by corticosteroid misuse.[39]

Acanthamoeba Keratitis

The agents used against Acanthamoeba organisms include biguanides (polyhexamethylene biguanide [PHMB] 0.02% solution, chlorhexidine 0.02%–0.06% solution) and diamidines (propamidine isethionate 0.1% solution, hexamidine 0.1% solution). These agents exhibit potent cysticidal activity but narrow therapeutic indices, resulting in significant epithelial and stromal toxicity during prolonged therapy.

Biguanides:

• Mechanism: Disrupts cytoplasmic membranes of trophozoites and cysts by binding to phospholipids.
• Kinetics: Limited corneal penetration; requires frequent dosing (hourly) for several weeks.
• Toxicity: Severe epithelial breakdown, stromal edema, and neurotrophic keratitis. Prolonged exposure can delay epithelial healing and lead to corneal melt in 10% to 15% of cases.

Diamidines:

• Mechanism: Interfere with DNA synthesis and membrane integrity.
• Kinetics: Good superficial corneal bioavailability but poor deep stromal penetration.
• Toxicity: Burning, photophobia, conjunctival hyperemia, and allergic blepharoconjunctivitis.[40]

Systemic safety: Both classes have minimal systemic absorption; however, combined long-term use (>3 months) increases the risk of ocular surface inflammation and fibrosis.

Summary:

• Major toxic kinetic mechanism: Nonselective cationic detergent effect on corneal epithelial membranes.
• Management challenge: Balancing cysticidal efficacy with tolerable epithelial toxicity through tapering or combination therapy.[41]

Table 8. Comparative Toxicokinetic Features

Abbreviations: PHMB, polyhexamethylene biguanide; TPK, therapeutic penetrating keratoplasty.

Integrative Perspective

From a toxicokinetic standpoint, Pythium keratitis represents a therapeutic paradox; antifungal agents are toxic yet ineffective, while antibacterial agents are effective but epitheliotoxic with prolonged exposure. In fungal keratitis, topical and systemic drugs may achieve deep tissue penetration but can produce dose- and duration-dependent epithelial degeneration and organ toxicity with long-term use. Treatment of Acanthamoeba keratitis, although vision-saving, carries the highest burden of ocular surface toxicity and necessitates vigilant epithelial support with lubricants, judicious corticosteroids (after cyst clearance), and amniotic membrane transplant (AMT). Understanding these drug–tissue kinetic interactions is crucial for tailoring regimens that maximize antimicrobial activity while minimizing host toxicity, ensuring visual rehabilitation and corneal integrity across all 3 conditions.[42]

History and Physical

Patients presenting with Pythium, fungal, or Acanthamoeba keratitis typically report acute ocular symptoms, including pain, redness, photophobia, watering, and reduced visual acuity. However, detailed history-taking reveals characteristic exposure patterns and treatment responses that help differentiate these conditions early. Pythium keratitis frequently occurs in individuals with recent exposure to agricultural settings or muddy water, especially during the monsoon or postmonsoon period. A history of minor corneal trauma with contaminated soil, paddy field water splash, or vegetative matter is common. Symptoms progress rapidly over 3 to 5 days, and a significant clue is a lack of improvement or worsening despite intensive antifungal therapy, leading clinicians to reconsider the initial diagnosis.

In contrast, fungal keratitis typically results from trauma, exposure to airborne fungal spores, or contact lens wear in humid environments. The onset is more indolent, progressing gradually over a week or more, and patients may report a blind spot or a foreign-body sensation. While pain is present, its severity correlates relatively more closely with the visible corneal findings. Patients may also have a history of topical corticosteroid use, which can exacerbate fungal invasion and deep stromal penetration.[22]

For Acanthamoeba keratitis, contact lens wear and water exposure (eg, swimming, rinsing lenses with tap water, or homemade solutions) are major risk factors. The hallmark clinical clue is disproportionately severe pain compared to early clinical signs, often described as stabbing or neuralgic in nature. In non–lens-wearing populations in resource-limited regions, exposure to contaminated water or trauma in soil-rich environments may be identified. Because symptoms may wax and wane for weeks to months, patients are often initially misdiagnosed with viral or fungal keratitis.

Physical examination using slit-lamp biomicroscopy further differentiates these conditions. Pythium keratitis classically demonstrates a dry, gray-white stromal infiltrate, with a reticular or tentacular pattern extending deep along stromal lamellae. Early endothelial plaques and dense hypopyon may develop even when the ulcer appears clinically inactive, reflecting rapid stromal invasion. Corneal melt and perforation may occur early if unrecognized. In fungal keratitis, the ulcer typically appears fluffy or raised with feathery margins and satellite lesions, indicating active granulomatous inflammation. The infiltrate is often centrally necrotic, and as the disease advances, a thick endothelial plaque and hypopyon may form.[43]

Conversely, Acanthamoeba keratitis initially presents with subtle epithelial changes, such as punctate erosions, pseudodendrites, or epithelial defects. A striking diagnostic sign is radial keratoneuritis, in which the corneal nerves appear thickened and inflamed, which accounts for the intense pain. As the disease progresses, a ring-shaped stromal infiltrate emerges, typically in the midstroma, accompanied by diffuse stromal edema. Despite aggressive early inflammation, corneal perforation is less common than in Pythium keratitis, unless secondary infection develops.

Overall, careful assessment of exposure history, disease progression, response to empirical antifungal therapy, and characteristic slit-lamp morphology enables early and accurate differentiation. Recognizing dry, rapidly destructive tentacular infiltrates that are unresponsive to antifungals strongly favors Pythium keratitis. Feathery infiltrates and satellite lesions are hallmarks of fungal infection, whereas severe pain disproportionate to the clinical appearance, especially in contact lens users, is highly suggestive of Acanthamoeba keratitis.[44]

History

A thorough history should focus on exposure, risk behaviors, and response to prior treatment. Table 9 summarizes the important elements of the patient history for each organism. Table 10 presents important physical examination cues, and Table 11 lists clinical diagnostic pearls. Table 12 presents a quick, clinical summary.

Table 9. Patient History Clues in Keratitis

A red flag strongly suggestive of Pythium keratitis: History of water or mud exposure with rapid worsening despite antifungals. Suspicion of Acanthamoeba keratitis increases if: Contact lens combined with water contact and extreme pain.[44]

Table 10. Physical Examination Characteristics of Keratitis

Abbreviations: TPK, therapeutic penetrating keratoplasty. 

Table 11. Clinical Differentiation Pearls for Clinicians

Table 12. Summary for Clinical Use

Need for Rapid Diagnosis and Treatment

Accurate differentiation at the bedside prevents inappropriate therapy:

• Pythium: Linezolid with azithromycin and early TPK
• Fungal: Natamycin and voriconazole are effective
• Acanthamoeba: Requires biguanides with neurotrophic pain control

Evaluation

Accurate evaluation of infectious keratitis relies on rapid microbiologic confirmation, imaging support, and assessment of treatment response. Because Pythium, fungal, and Acanthamoeba keratitis often present with similar clinical findings, a structured diagnostic approach aligned with international standards (American Academy of Ophthalmology [AAO]), International Council of Ophthalmology, and All India Ophthalmological Society) is essential to prevent delays in definitive therapy. Table 16 summarizes the recommendations based on the national guidelines.

Initial Bedside Evaluation

• Slit-lamp biomicroscopy: – Pythium: Dry reticular/tentacular infiltrate, early endothelial plaques. (See Image. Clinical Features of Pythium Keratitis.) and (See Image. Slit-Lamp Examination of Pythium Keratitis.) – Fungal: Feathery infiltrates, satellite lesions. (See Image. Slit-Lamp Examination of Fungal Keratitis.) – Acanthamoeba: Radial keratoneuritis and disproportionate pain. (See Image. Slit-Lamp Examination of Acanthamoeba Keratitis.)
• Fluorescein staining: Maps epithelial loss; dendritiform lesions suggest early Acanthamoeba keratitis
• Confocal microscopy (in vivo): A rapid, noninvasive test with high diagnostic value – Pythium: Long aseptate ribbon-like filaments – Fungal: Septate branching hyphae – Acanthamoeba: Double-walled cysts along nerves (highly specific)[45]

Laboratory Microbiology (Gold Standard)

Performed urgently in all patients with suspected microbial keratitis according to the American Academy of Ophthalmology guidelines. Table 13 summarizes the laboratory testing results for each organism.

Table 13. Laboratory Testing in Keratitis

Abbreviations: KOH, potassium hydroxide; PAS, periodic acid-Schiff; SDA, Sabouraud dextrose agar;

Stains useful for rapid differentiation: • PAS: Highlights Pythium filaments • GMS: Strongly positive only in fungi • Calcofluor White: Bright hyphae/cysts (needs ultraviolet scope)

Molecular Diagnostics (Advanced and Confirmatory)

International guidelines recommend PCR when smear or culture is inconclusive or an urgent diagnosis is required:

• Pythium spp: ITS gene region PCR and COX2 gene sequencing
• Fungal: Panfungal PCR with species identification
• Acanthamoeba spp: 18S ribosomal DNA PCR or real-time PCR. These tools provide high accuracy (>95%) and early species-level confirmation.[46] Table 14 summarizes the imaging and other testing.

Table 14. Imaging & Ancillary Investigations

Abbreviations: AS-OCT, anterior segment optical coherence tomography.

Radiologic imaging is rarely required unless scleral or intraocular extension is suspected.

Therapeutic Trial Response 

Monitoring the response within the first 48 to 72 hours provides additional differentiation, as described in Table 15.[47]

Table 15. Therapeutic Trials by Organism

Key Diagnostic Pearls

If the ulcer worsens on antifungals → Pythium keratitis is likelyIf severe pain exceeds clinical signs → suspect Acanthamoeba keratitisIf feathery edges and satellite lesions → fungal keratitis

Early confocal microscopy and microbiological sampling are the global standards for differentiation.

• Day 1: Smear, culture, and confocal microscopy
• If unclear: PCR testing
• Management: Initiate organism-directed therapy based on microbiologic results and early treatment response [48]

Table 16. International Keratitis Guidelines

Abbreviations: PCR, polymerase chain reaction.

Treatment / Management

Early, organism-specific therapy is critical because misdirected treatment (eg, antifungals for Pythium spp or corticosteroids for active Acanthamoeba keratitis) rapidly worsens visual outcomes. Management includes targeted antimicrobial therapy, control of pain and inflammation, and surgical intervention when necessary.

Treatment of Pythium Keratitis (Antioomycete Strategy) Pythium lacks chitin and ergosterol, making it intrinsically resistant to most antifungals.[12] Table 17 summarizes the first-line treatment according to the Indian Pythium Study Group and the AIOS.(A1)

Table 17. First-Line Medical Therapy for Pythium Keratitis

Therapy should continue until complete resolution (8–12 weeks).

Criteria for TPK

Surgical intervention should be earlier if any of the following are present:

• Rapid stromal melt or impending perforation
• Large central infiltrate (>6 mm)
• No improvement within 48 to 72 hours of antioomycete therapy
• Limbal extension or endothelial plaque progression

 Large-graft TPK is (8–10 mm margin) to ensure full organism clearance. However, the recurrence risk is high, so topical therapy should continue after surgical intervention.[49](B2)

Management of Fungal Keratitis

The goal is to eradicate fungal hyphae and prevent stromal necrosis. Table 18 lists the first-line treatment options per the American Academy of Ophthalmology guidelines.

Table 18. First-Line Antifungals

Adjunct systemic therapy: – Oral voriconazole 200 mg twice daily for deep stromal involvement or anterior chamber extension – Avoid corticosteroids during the acute phase [37](A1)

Indications for surgical intervention:

• Progressive infiltrate despite maximum medical therapy (72 to 96 h)
• Large central ulcer with thinning
• Descemet detachment or perforation
• Dense endothelial plaque with unresponsive hypopyon

Procedures:

• Therapeutic penetrating keratoplasty
• Tissue adhesive (glue) with a bandage contact lens for a small perforation
• AMT for neurotrophic surface support [50]
(B3)

Management of Acanthamoeba Keratitis

Both trophozoites and cysts should be treated. Corticosteroids worsen early disease; therefore, they should be deferred until cyst clearance is confirmed. Table 19 summarizes treatment according to UK and European Union consensus.Corticosteroids should be delayed until cyst clearance is confirmed, as they worsen early disease.

Table 19. First-Line Medical Therapy

Abbreviations: PHMB, polyhexamethylene biguanide.

Therapy should be continued for 3 to 6 months, depending on symptom recurrence.

Corticosteroid use:

Corticosteroids should be considered only when:

• Clear improvement with negative confocal or PCR
• Persistent inflammation after the trophozoite kill
• Introduce 4 to 6 weeks after treatment; start low dose every 12–24 h 

Surgical treatment:

• AMT for persistent epithelial defects
• Therapeutic penetrating keratoplasty only for perforation or end-stage scarring
• Recurrence risk is high if cysts remain [51]

Adjunctive Measures for All 3 Organisms

• Cycloplegics for pain control
• Aggressive lubrication for surface protection
• Intraocular pressure–lowering agents for secondary glaucoma
• Avoid empiric corticosteroids until the organism is confirmed
• Avoid contact lens wear throughout treatment

Table 20 lists treatment pearls for each organism.

Table 20. Treatment Pearls

Abbreviations: PHMB, polyhexamethylene biguanide.

Management Escalation Algorithm (Clinical Pathway)

1. Suspected infectious keratitis  2. Perform corneal scraping for smear and culture, and obtain confocal microscopy immediately 3. Start empirical antifungal (natamycin) while awaiting smear results 4. Assess response after 48–72 h. Table 21 describes the next actions [52]

Table 21. Treatment Algorithm for Keratitis

Reassess every 48 hours. Consider TPK for progressive disease.

• Pythium is a surgical disease: Treat early and escalate with rapid progression.
• Fungal keratitis is a slow killer: Treat aggressively and continue long-term therapy.
• Acanthamoeba spp is a painful survivor: Treat persistently, avoid early corticosteroids. 

Differential Diagnosis

Because Pythium, fungal, and Acanthamoeba keratitis share overlapping clinical features, such as stromal infiltrates, hypopyon, and epithelial defects, they are frequently misdiagnosed, especially at initial presentation. Several other infectious and inflammatory entities should also be considered. Careful integration of history, slit-lamp examination, microbiology, and confocal imaging is essential to reach the correct diagnosis. Table 22 compares the organisms in the differential diagnosis. Table 23 reviews the diagnostic pitfalls of the various causes of keratitis.

Key Differential Diagnoses

Fungal keratitis

Often confused with Pythium keratitis due to filamentous growth and a similar infiltrate appearance. – Feathery margins, satellite lesions – Better initial response to natamycin or voriconazole – Septate hyphae on microscopy [53]

Acanthamoeba keratitis

Major mimic in early disease. – Severe pain out of proportion to signs – Radial keratoneuritis – Ring infiltrate in late stages – Cysts on confocal microscopy or PCR [54]

Bacterial keratitis (especially Pseudomonas spp)

– Rapid course that resembles that of Pythium keratitis – Suppurative stromal melt, dense purulent discharge – Responds rapidly to fortified antibiotics. Please see StatPearls' companion resource, "Nocardia Keratitis," for further information.

Herpetic keratitis (herpes simplex virus/varicella zoster virus)

– Dendritiform lesions early suggest a neurotrophic ulcer – Reduced corneal sensation – Worsens with topical corticosteroids. Please see StatPearls' companion resource, "Herpes Zoster Ophthalmicus," for further information.

Noninfectious masqueraders – Autoimmune melt (eg, rheumatoid arthritis, Mooren ulcer) – Sterile infiltrates in contact lens users – Peripheral ulcerative keratitis [55]

Table 22. Differentiating Clinical Features 

Table 23. Diagnostic Pitfalls & Prevention

Abbreviations: GMS, Gomori methenamine silver; PAS, periodic acid-Schiff; PCR, polymerase chain reaction.

Decision-Making Rule of Thumb (Clinical Pearl Box)

• Dry, tentacular infiltrate with antifungal failure: Suspect Pythium infection
• Feathery edges with vegetable trauma: Suspect fungal keratitis
• Contact lens with severe pain and neural signs: Suspect Acanthamoeba keratitis
• Purulent discharge and rapid stromal thinning: Suspect bacterial keratitis
• Neurotrophic ulcer with dendrites: Suspect herpetic keratitis

The most challenging diagnostic overlap occurs between Pythium and fungal keratitis, as both exhibit a filamentous appearance. However, Pythium keratitis typically presents with a dry, reticular stromal infiltration and early endothelial plaques, and it rapidly progresses despite antifungal therapy. Acanthamoeba keratitis is characterized by disproportionate pain, perineural infiltrates, and ring lesions, particularly among contact lens wearers. Bacterial keratitis is characterized by purulent discharge and a rapid response to fortified antibiotics, whereas herpetic keratitis typically presents with reduced sensation and dendritic lesions. Accurate differentiation prevents vision-threatening delays in treatment, enabling organism-specific therapy that dramatically improves prognosis.[48]

Pertinent Studies and Ongoing Trials

The evolution of diagnostic and therapeutic strategies for Pythium, fungal, and Acanthamoeba keratitis has been supported by a growing body of clinical and translational research. Recent studies have focused on improving early diagnosis, optimizing antioomycete drug protocols, novel antifungal delivery systems, and cysticidal agents. The following section is a detailed review of critical evidence and emerging clinical trials that justify current management recommendations. Table 24 describes the results of the trials. Oomycete biology (lack of chitin & ergosterol) explains intrinsic resistance to most antifungal agents.

Table 24. Key Evidence and Trials for Pythium Keratitis 

Emerging investigational agents:

• Minocycline
• Isavuconazole
• Novel antioomycete peptides

These studies support antibiotic-based therapy and early TPK, rather than traditional antifungal regimens, to prevent delays that can lead to melt or perforation.[56]

Fungal Keratitis (Table 25)

Table 25. Key Trials and Innovations for Fungal Keratitis

Other critical findings:

• High failure rates with delayed antifungal therapy
• Voriconazole remains vital for Aspergillus infections
• PhotoActivated chromophore for keratitis-corneal cross (PACK-CXL) evaluated as an adjunct is promising in fungal but ineffective in Pythium keratitis

Device-based advances:

• Intrastromal antifungal injections
• Nanocarrier-based drug delivery [57]

These findings reinforce natamycin as first-line, identify voriconazole for deeper lesions, and discourage routine CXL in Pythium keratitis.

Acanthamoeba Keratitis

The primary mechanistic focus of research on Acanthamoeba keratitis is the cyst stage. Table 26 describes the major findings.

Table 26. Study Findings for Acanthamoeba Keratitis 

Abbreviations: AK, Acanthamoeba keratitis; PHMB, polyhexamethylene biguanide.

Novel therapies under investigation:

• Miltefosine (antileishmanial): Superior cysticidal activity in refractory disease
• Photodynamic therapies: Laboratory models
• Gene-expression targeting: Encystment pathways

These findings suggest prolonged, staged therapy and delayed corticosteroid initiation based on cyst monitoring.[58]

Changes to Keratitis Treatment

Tables 27 and 28 describe the impact and changes to clinical practice.

Table 27. Integrated Clinical Impact Summary

Abbreviations: PACK-CXL, photoactivated chromophore for keratitis-corneal cross; PCR, polymerase chain reaction.

Table 28. Changes in Clinical Practice for Keratitis

Abbreviations: PACK-CXL, photoactivated chromophore for keratitis corneal cross; TPK, therapeutic penetrating keratoplasty.

Current management protocols are rooted in strong clinical evidence showing:

Pythium keratitis: A surgical and antibiotic diseaseFungal keratitis: A medical and selective surgical diseaseAcanthamoeba keratitis: A long-duration cysticidal therapy disease

Ongoing research will likely expand the use of targeted therapies, reduce morbidity, and improve visual outcomes, particularly among high-risk tropical populations.[59]

Treatment Planning

Treatment planning must be organism-specific, systematic, and time-bound because incorrect initial therapy significantly worsens prognosis, particularly in Pythium and Acanthamoeba keratitis. The framework below integrates dosages, response-based escalation, adjunctive treatment, and surgical indications consistent with key clinical trials.[42] Table 29 lists treatment pearls for keratitis due to each organism.

Treatment Planning for Pythium Keratitis

Time = Vision → aim for rapid organism control before stromal melt

Initial antioomycete regimen (initiate immediately once suspected)

Topical linezolid is typically administered at a concentration of 0.2% to 0.5%, with intensive dosing every 1 to 2 hours during the day and every 2 to 3 hours at night during the acute phase of infection. Topical azithromycin 1% may be used as an adjunctive therapy and is generally instilled every 2 to 3 hours. In cases with deep stromal involvement or severe disease, systemic linezolid is prescribed at 600 mg twice daily for 10 to 14 days, with close monitoring for systemic adverse effects.[42]

Adjunctive agents if indicated: • Minocycline, 100 mg/day • Topical isavuconazole in refractory cases [13]

Supportive therapy

• Cycloplegics
• Intensive lubrication
• Intraocular pressure control, if necessary

Escalation criteria for urgent surgery

Perform TPK when any of the following occur:

• Clinical deterioration within 48 to 72 hours
• Descemet membrane involvement (eg, endothelial plaque)
• Stromal melt or impending perforation
• Large central ulcer (> 6 mm)
• Limbus or scleral extension [60]

Large graft margins (≥ 1 mm in circumference) should be achieved to reduce recurrence risk. Continue antioomycete therapy post-TPK for at least 2 to 3 weeks. Please see StatPearls' companion resource, "Cornea Transplantation," for further information.

Treatment Planning for Fungal Keratitis

Drug selection based on etiology

• Fusarium spp: Natamycin 5% hourly for 48 hours, then taper every 2 to 3 hours
• Aspergillus spp: Voriconazole 1% hourly
• Candida spp: Amphotericin B 0.15%

Systemic therapy:

• Oral voriconazole 200 mg twice daily if deep stromal or anterior chamber involvement. Please see StatPearls' companion resource, "Cytomegalovirus Corneal Endotheliitis," for further information.

Adjunctive tools

• Epithelial ebridement to improve drug penetration
• Intrastromal antifungal injections for recalcitrant hyphae
• Photoactivated chromophore for keratitis–corneal cross-linking is not recommended for Pythium spp, selective for fungal keratitis

Surgical indications

• Nonresponse after 72 to 96 hours of maximal therapy
• Severe thinning or perforation
• Endothelial plaque unresponsive to medication

Surgical options:

• TPK or lamellar keratoplasty
• Cyanoacrylate glue with a bandage contact lens
• AMT for neurotrophic disease. Please see StatPearls' companion resource, "Iritis," for further information.

Treatment Planning for Acanthamoeba Keratitis

Staged protocol

In the early stage of epithelial disease, management focuses on intensive topical antiamebic therapy, typically using polyhexamethylene biguanide (PHMB) 0.02% administered hourly in combination with propamidine 0.1%. With stromal involvement, treatment with topical agents is continued, and systemic nonsteroidal anti-inflammatory drugs with adequate pain control are added for inflammation. Following successful eradication of trophozoites, delayed initiation of low-dose topical corticosteroids may be considered in selected cases to manage persistent inflammation, with careful monitoring for recurrence. In chronic disease with significant corneal scarring and fibrosis, keratoplasty may be required to restore visual function.[1]

• Total duration: 3–6 months
• Strict avoidance of early corticosteroids due to cyst proliferation

Confocal microscopy–guided tapering

• Reduce dosing only after cyst clearance evidence
• Reinstate intensive therapy if pain or infiltrates recur

Surgical planning

• Reserved for perforation or visual rehabilitation
• High recurrence risk if cysts remain in the host rim
• An AMT is often required for persistent epithelial defects

Unified response escalation timeline (applicable to all 3 etiologies)

Clinical response should be reassessed at 48 to 72 hours after initiating therapy. If improvement is significant, the current treatment regimen should be continued with close monitoring. If improvement is minimal, repeat corneal smears should be performed, and therapy should be modified based on the revised clinical suspicion. If the clinical condition worsens, urgent consideration of TPK is warranted, particularly in cases of suspected or confirmed Pythium keratitis.[6]

Table 29. Clinical Strategy Pearls 

Abbreviations: PHMB, polyhexamethylene biguanide.

Treatment Strategy

Pythium keratitis is a surgical disease → treat aggressively earlyFungal keratitis is a medical disease → treat long and strongAcanthamoeba keratitis is a persistent cystic disease → treat slowly, avoid corticosteroids early in the disease [12]

Toxicity and Adverse Effect Management

Differentiating Pythium, Fungal, and Acanthamoeba Keratitis

Therapy for microbial keratitis often requires high-frequency topical regimens and prolonged treatment durations, which can cause significant ocular surface toxicity. Toxicity prevention and management must be proactive, organism-specific, and continuously monitored.

Pythium Keratitis

Antifungal therapy (not antifungal therapy) carries a risk of epithelial toxicity.

Primary toxicities

Topical linezolid may cause mitochondrial toxicity, which can manifest as epithelial defects and ocular surface haze; therefore, weekly monitoring of epithelial integrity is recommended during therapy. Topical azithromycin is generally well tolerated but may cause burning, dryness, or allergic conjunctivitis; the dosing frequency should be reduced if epithelial compromise develops. Systemic linezolid carries a risk of myelosuppression and, with prolonged use, optic neuropathy. Accordingly, weekly monitoring of the complete blood count is advised, and the drug should be discontinued promptly if visual symptoms occur.

Management strategies

• Lubrication with preservative-free formulations
• Temporary dose reduction if epitheliopathy is severe
• Earlier TPK if toxicity limits drug tolerance
• AMT for nonhealing epithelial defects [61]
• Avoid antifungal therapy alone because it is ineffective and toxic in Pythium keratitis.

Fungal Keratitis

Primary toxicities

Natamycin 5% may cause epithelial edema and punctate keratopathy, but it is generally considered the most surface-friendly antifungal agent; however, frequent dosing can cause ocular irritation. Topical voriconazole is associated with stromal toxicity and burning, and systemic administration increases hepatotoxicity risk, necessitating liver function monitoring when administered orally or intravenously. Amphotericin B has the lowest ocular surface tolerance among antifungal agents and can cause severe epithelial toxicity and stromal necrosis; it should be used cautiously and reserved for selected cases.

Toxicity mitigation

• Epithelial debridement to improve penetration and reduce the dose of medications
• Taper once clinical improvement is observed
• Use preservative-free, antifungal formulations when available
• Manage neurotrophic keratopathy, a frequent complication. Please see StatPearls' companion resource, "Therapeutic Keratoplasty," for further information.

Corticosteroids should be used only in the late healing phase, in small doses, and under close supervision.

Acanthamoeba Keratitis

Primary toxicities

Toxicity results from the detergent action of biguanides/diamidines on host membranes. Biguanides, such as PHMB and chlorhexidine, are associated with significant ocular surface toxicity, including severe punctate keratitis and, in advanced cases, stromal melt. This toxicity is most pronounced with prolonged hourly dosing. Diamidines may cause allergic blepharoconjunctivitis and should therefore be used judiciously, primarily as adjunctive agents for synergistic effect rather than as monotherapy.

Pain-related complications:

• Neurotrophic keratitis
• Corneal anesthesia
• Recurrent epithelial breakdown

Management strategies

• Frequent lubrication
• Pain control (eg, cycloplegia, nonsteroidal antiinflammatory drugs)
• AMT for persistent epithelial defects
• Delay corticosteroids until cyst clearance (4–6 weeks)
• Intraocular pressure management of secondary glaucoma [62]

Tapering should be slow because rapid reduction can cause cyst resurgence and clinical relapse.

Cross-Condition Toxicity Considerations

Long-term topical toxicity should be addressed by switching to preservative-free formulations to minimize ocular surface damage during prolonged therapy. Contact lens use should be strictly avoided throughout the treatment period to reduce the risk of persistent infection and delayed epithelial healing. In cases of secondary bacterial infection, management should be guided by culture-directed antibiotic therapy to ensure targeted and effective treatment. Ocular surface inflammation may be managed with the careful, delayed introduction of low-dose topical corticosteroids tailored to the underlying organism and clinical response. If intraocular pressure increases, topical β-blockers are preferred as first-line agents; prostaglandin analogs should be avoided because they may exacerbate inflammation. The following are important considerations:

• Begin toxicity monitoring from the first day.
• Adjust dosing interval based on epithelial health.
• Provide ocular surface protection with lubrication with a bandage contact lens in selected cases.
• Use confocal microscopy or PCR to avoid misdirected toxic treatments.
• Consider AMT if epithelial compromise persists despite tapering.[63]

Practical Pearls

• Pythium therapy is less toxic than antifungals, but delayed surgery can result in catastrophic outcomes.
• Antifungals are potent but toxic, and should be tapered as soon as the organism load reduces.
• Acanthamoeba therapy is the most toxic. Cysticidal efficacy should be balanced with ocular surface protection.
• Toxicity management is as critical as antimicrobial potency to preserve vision.

Staging

A standardized staging system helps to:

1. Guide treatment escalation
2. Plan surgical timing
3. Determine visual prognosis

The following practical, clinically applicable staging framework integrates the most widely used classification elements and proposed refinements from recent literature, including conceptual guidance from Gurnani and Kaur (Proposed Clinical Severity Model). The staging model is summarized in Table 30; Table 31 lists the distinguishing features of each organism; and Table 32 presents therapy implications for each stage.[22]

Table 30. Proposed Gurnani–Kaur Composite Staging System for Infectious Filamentous Keratitis Differentiation 

Abbreviations: AC, anterior chamber; AK, Acanthamoeba keratitis; PCR, polymerase chain reaction; TPK, therapeutic penetrating keratoplasty.

Severity Score Additions

• Pain score (in Acanthamoeba keratitis)
• Exposure history-based risk weighting
• Treatment response is critical for distinguishing Pythium from other types of keratitis [6]

Table 31. Organism-Specific Staging Clues

Pythium keratitis may progress rapidly, and early misclassification can lead to irreversible loss of the globe.

Table 32. Treatment Implications by Stage

Abbreviations: PHMB, polyhexamethylene biguanide; TPK, therapeutic penetrating keratoplasty. 

Clinical Pearls 

• Pythium keratitis: Endothelial plaque should prompt escalation to stage 3 or 4 immediately
• Fungal keratitis: Gradual melt with feathery margins
• Acanthamoeba keratitis: Pain is disproportionately severe in the early stages

Summary

The Gurnani–Kaur staging helps rapidly triage aggressive cases, enabling:

• Early antifungal therapy in Pythium keratitis
• Proper antifungal selection in fungal ulcers
• Prolonged cysticidal therapy with delayed corticosteroids in Acanthamoeba keratitis
• Early surgical referral before perforation [22]

Prognosis

The prognosis in microbial keratitis is primarily determined by the causative organism, the time to a correct diagnosis, the promptness of appropriate therapy, and the disease stage at presentation. Delays in organism-specific treatment significantly worsen outcomes, particularly in Pythium and Acanthamoeba infections. Table 33 compares the prognosis of the 3 conditions.

Prognostic Overview by Etiology

Pythium Keratitis (Most Aggressive Course)

• Poor prognosis if misdiagnosed initially as fungal keratitis
• Vision salvage is closely tied to early antifungal therapy and early TPK
• Delayed intervention results in rapid corneal melt, perforation, and scleral extension [29]

The presence of an endothelial plaque is a strong predictor of the need for TPK. A large corneal infiltrate (> 6 mm) is associated with higher rates of disease recurrence and graft failure. Limbal involvement signifies severe disease and carries a substantial risk of globe loss. Additionally, a delay in initiating appropriate therapy beyond 72 hours is associated with worse outcomes and overall prognosis. However, with appropriate, timely treatment, anatomical globe salvage has improved from less than 30% to greater than 70% in results from recent series.

Fungal Keratitis (Variable Prognosis)

• Moderate to guarded prognosis, depending on the pathogen and penetration depth
• Better outcomes with:
  • Early natamycin for Fusarium spp
  • Voriconazole for Aspergillus spp [19]

Complications leading to worse outcomes

• Macular scarring can lead to permanent visual loss
• Secondary glaucoma
• Postkeratoplasty recurrence [64]

Early response within 72 to 96 hours predicts a favorable outcome.

Acanthamoeba Keratitis (Slow but Persistent)

• Prognosis is highly dependent on timely diagnosis
• Late presentation is common, and vision is often affected despite organism eradication

Key prognostic issues

• Chronic keratopathy and neurotrophic sequelae
• Recurrence is common if cysts remain in the host rim
• Keratoplasty during the active phase leads to high graft failure [65]

If treated early with cysticidal therapy, functional vision is usually recovered.

Table 33. Prognostic Comparison Table

Abbreviations: TPK, therapeutic penetrating keratoplasty.

Predictors of Poor Visual Outcome (All Causes)

Delayed initiation of targeted therapy allows deeper stromal invasion and cyst maturation, leading to more aggressive disease and worse outcomes. Central large corneal ulcers are associated with macular scarring, which significantly limits final visual acuity even after infection resolution. Corneal thinning or perforation often necessitates surgical intervention, and graft survival in such cases is unpredictable. Endothelial involvement increases anterior chamber inflammation and the risk of recurrence, complicating medical and surgical management. Systemic immune compromise further contributes to delayed healing and a prolonged clinical course.[48]

Prognosis Pearls 

Pythium keratitis: Diagnosis late = vision lostFungal keratitis: Treatment late = cornea lostAcanthamoeba keratitis: Corticosteroids early = disease worsened

Patient-Centered Prognostic Counseling

Patients should be informed that:

• Treatment duration may be prolonged (weeks to months).
• Even with the eradication of the organism, residual scarring may necessitate optical or therapeutic keratoplasty.
• Avoiding contact lenses and water exposure during treatment is critical to prevent recurrence.

Summary

Fungal infections often have the best outcomes, whereas Pythium keratitis has the worst. Acanthamoeba keratitis outcomes vary. Rapid recognition and pathogen-specific management are the strongest predictors of visual success.[66]

Complications

Microbial keratitis can lead to a broad spectrum of serious ocular complications, including corneal tissue destruction, severe inflammation, delayed identification of the causative organism, and toxicity from prolonged therapy. Complication risk and pattern vary significantly by pathogen. Table 34, Table 35, Table 36, and Table 37 summarize complications attributable to the organism, treatment, surgical intervention, and psychosocial factors, respectively.

Table 34. Major Complications by Etiology

Abbreviations: AC, anterior chamber; TPK, therapeutic penetrating keratoplasty.

Table 35. Treatment-Related Complications

Abbreviations: AK, Acanthamoeba keratitis; CL, contact lens; PHMB, polyhexamethylene biguanide.

Table 36. Surgical Complications

Abbreviations: TPK, therapeutic penetrating keratoplasty.

Delayed referral or emergent large-graft Pythium keratitis is associated with increased postoperative complications.

Table 37. Systemic and Psychosocial Complications

Key Clinical Pitfalls

• Misdiagnosing Pythium keratitis as fungal keratitis: Antifungal therapy delays effective care and worsens prognosis
• Early corticosteroids in Acanthamoeba keratitis: Explosive cyst proliferation causes rapid deterioration
• Delayed surgical intervention: Irreversible perforation and melt
• Misdiagnosis of endothelial plaque: Delayed TPK can lead to globe loss
• Toxicity misdiagnosed: Worsened scarring and poor visual outcomes

Summary

Severity of potential complications: Pythium > Acanthamoeba ≥ fungal keratitis. Rapid recognition, organism-targeted therapy, and timely surgical planning are the most powerful tools for reducing complications.[67]